retatrutide clinical trial dosage ESC 2024: improves lipid and cardiovascular risk profile in Phase II VisualAbstract: Retatrutide reduces body weight

In Phase 2 data, each dose step delivered approximately 3 additional percentage points of weight loss: 1 mg produced 8.7%, 4 mg produced 15.2%, 8 mg produced 21.1%, and 12 mg produced 24.2%

Two TikTok accounts with millions of followers were used to impersonate legitimate weight-loss influencers who had criticised fake weight-loss drugs

With a trusted safety profile and consistent branding, it maintains a commanding position in North America and Europe

Emerging evidence suggests that dual GLP-1/GIP agonists like tirzepatide may offer a more favorable gastrointestinal profile in some patients, potentially improving adherence (Kim et al., 2025)